Top 3 Health Care Stocks That May Rocket Higher In Julybenzinga_article·Jul 20 at 05:03 AMLEGN-13.28%IRD+8.77%
Cantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)Tip Ranks·Jul 10 at 06:36 AMIRD+8.77%
Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target UnchangedTip Ranks·Jul 9 at 09:55 AMIRD+8.77%
Opus Genetics to release 3-month Cohort 1 topline data for OPGx-BEST1 trial in September 2026PUBT·Jul 9 at 06:01 AMIRD+8.77%
Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price TargetTip Ranks·Jul 6 at 12:15 PMIRD+8.77%
Opus Genetics posts press release on FDA alignment for OPGx-LCA5 Phase 3 trial designPUBT·Jul 6 at 06:02 AMIRD+8.77%
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes | IRD Stock NewsStockTitan·Jun 26 at 12:15 AMIRD+8.77%
Opus Genetics, Inc. Stock 12‑Month Price Target Raised to $10.69, Implies 163% UpsideTradingView·Jun 17 at 11:20 PMIRD+8.77%
Opus Genetics shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $8 price target.benzinga_article·Jun 17 at 12:04 PMIRD+8.77%
Opus Genetics Highlights Advancing Inherited Retinal Disease PipelineTip Ranks·Jun 16 at 11:27 AMIRD+8.77%
